Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037922 | 0.80 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL94916 | 0.77 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL16513160 | 0.77 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL2639252 | 0.77 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL612167 | 0.77 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL9010837 | 0.77 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL7168417 | 0.77 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL4404534 | 0.77 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2AKDM4ETDP1 | |
| SCHEMBL11270399 | 0.73 | HSD17B10 (0.49) | ALDH1A1MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL5523925 | 0.73 | DUSP3 (0.38) | ALDH1A1MEN1KMT2AKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814504-A1 | APTAMERS FOR PERSONAL CARE APPLICATIONS | The Procter & Gamble Company (US) | 2021-05-05 | — | — | EP | claimed |
| EP-3814505-A1 | APTAMERS FOR HAIR CARE APPLICATIONS | The Procter & Gamble Company (US) | 2021-05-05 | — | — | EP | claimed |
| EP-3401683-A1 | DIAGNOSING METABOLIC DISEASE BY THE USE OF A BIOMARKER | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2018-11-14 | — | — | EP | claimed |
| CN-101065110-A | Dried form of aqueous bile acid formulation: preparation and use thereof | SEO-HONG YOO (US) | 2007-10-31 | — | — | CN | claimed |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | Genetic Intelligence, Inc | 2023-08-31 | — | — | US | disclosed |
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | GENETIC INTELLIGENCE INC (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4165185-A2 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | Genetic Intelligence, Inc, New York, NY (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2021252903-A2 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | GENETIC INTELLIGENCE, INC, NEW YORK, NY (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3814504-A1 | APTAMERS FOR PERSONAL CARE APPLICATIONS | The Procter & Gamble Company (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3814505-A1 | APTAMERS FOR HAIR CARE APPLICATIONS | The Procter & Gamble Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-110382709-A | Adapter capable of conversion | 维尔道应用技术大学 | 2019-10-25 | — | — | CN | disclosed |
| EP-3401683-A1 | DIAGNOSING METABOLIC DISEASE BY THE USE OF A BIOMARKER | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2018-11-14 | — | — | EP | disclosed |
| CN-101065110-A | Dried form of aqueous bile acid formulation: preparation and use thereof | SEO-HONG YOO (US) | 2007-10-31 | — | — | CN | disclosed |
| CN-101039699-A | Methods and compositions for reducing toxicity of a pharmaceutical compound | YOO SEO HONG (US) | 2007-09-19 | — | — | CN | disclosed |
| CN-1942592-A | Neisseria gonorrhoeae detection | STATE OF QUEENSLAND ACTING THR (AU) | 2007-04-04 | — | — | CN | disclosed |
| US-7192936-B2 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| CN-1122600-A | Inhibitors of second messenger cell signaling | CELL THERAPEUTICS INC (US) | 1996-05-15 | — | — | CN | disclosed |
| EP-0502690-A2 | Cyclopropane derivative | Ajinomoto Co., Inc. (JP) | 1992-09-09 | — | — | EP | disclosed |
| CN-1048546-A | Substituted imidazo-fused 6 unit heterocycle as angiotensin II antagonism medicine | MERCK & CO INC (US) | 1991-01-16 | — | — | CN | disclosed |
| EP-0391592-A1 | Process for the enzymatic synthesis of nucleosides | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | FNIP1, FN1, TNNC1 | ALDH1A1 4324/4885MEN1 3817/4885KMT2A 4188/4885 |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | TARDBP, FUS, RBM17 | ALDH1A1 4065/4885MEN1 4364/4885KMT2A 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.